Stress Hormone Signals Push Breast Cancer Cells in Opposite Directions Depending on Estrogen Receptor Status

Chronic stress has long been suspected of feeding cancer, but the biology behind that link has remained stubbornly murky. Now a new study published in Medical Oncology offers one of the clearest mechanistic explanations yet for why the same stress signal can help one breast tumor thrive while restraining another. The research, led by Hannah P. Priyanka and colleagues working across institutions in Chennai, India, demonstrates that the fate of breast cancer cells exposed to beta-2 adrenergic stimulation depends decisively on whether those cells carry functional estrogen receptors, the molecular markers that define one of the most important clinical subtypes of the disease.

The sympathetic nervous system, the body’s fight-or-flight machinery, communicates with tissues through neurotransmitters such as norepinephrine, which bind to adrenergic receptors on cell surfaces. The predominant subtype in many tissues is the beta-2 adrenoceptor, a G protein-coupled receptor that triggers cascades of intracellular messengers when activated. Epidemiological and experimental work over the past two decades has implicated this pathway in cancer progression, with studies showing that beta-blocker drugs can reduce secondary tumor formation in breast cancer patients and that sympathetic activation can induce a metastatic switch in primary breast tumors. What has been missing is a precise account of how this signaling intersects with hormone receptor biology inside tumor cells themselves.

To dissect that intersection, the team turned to two of the most widely used breast cancer cell lines in laboratory research: MCF-7 cells, which are estrogen receptor positive, and MDA-MB-231 cells, which lack the estrogen receptor. Both were grown in vitro and treated with terbutaline, a selective beta-2 adrenoceptor agonist, at two concentrations spanning a physiological range, and with propranolol, a non-selective beta-adrenergic antagonist, to test whether observed effects could be blocked. The researchers then measured a battery of outcomes: cell cycle progression as a readout of proliferation, levels of the pro-angiogenic factors VEGF-A and VEGF-C by enzyme-linked immunosorbent assay, activation of the ERK and CREB signaling proteins, nitric oxide production via the Griess assay, and expression of two cancer-associated microRNAs, miR-21 and miR-191, by quantitative PCR.

The results were strikingly divergent. In the estrogen receptor positive MCF-7 cells, terbutaline acted as an accelerant: it enhanced proliferation, boosted VEGF-C expression, raised miR-191 levels, and strengthened ERK phosphorylation, the activated form of the signaling protein. In the estrogen receptor negative MDA-MB-231 cells, the very same drug produced the opposite effect on every one of those measures, attenuating proliferation, VEGF-C output, miR-191 expression, and p-ERK signaling. In other words, a single receptor, engaged by a single ligand, pushed the two cell types in opposite biological directions, with the estrogen receptor status of the cell acting as the molecular switch that determined which way the machinery would turn.

Not everything split along receptor lines, however, and those exceptions proved equally informative. CREB phosphorylation, a second major signaling arm downstream of beta-2 adrenoceptors, was enhanced in both cell lines regardless of estrogen receptor status. VEGF-A, the canonical driver of blood vessel growth, was downregulated in both. Nitric oxide production and miR-21 expression both increased in an estrogen receptor independent fashion. These findings suggest that while the divergent outcomes in proliferation and VEGF-C regulation likely arise from selective engagement of ERK-dependent pathways shaped by estrogen receptor crosstalk, some beta-adrenergic effects operate through mechanisms that bypass the estrogen receptor entirely, underscoring the layered complexity of adrenergic signaling in breast cancer.

The microRNA data add an epigenetic dimension to the story. miR-191, which tracked precisely with the opposing proliferative responses, is a recognized player in breast cancer biology, and prior work has shown that estrogen can activate the miR-191/425 cluster in a manner that depends on estrogen receptor status. miR-21, by contrast, rose in both cell lines after terbutaline treatment, consistent with its reputation as a broadly expressed oncomir associated with multiple breast cancer subtypes. The finding that adrenergic stimulation can tune these regulatory RNAs differently depending on hormone receptor context hints that stress hormones may reshape the epigenetic landscape of tumors in a subtype-specific way.

Propranolol provided the pharmacological counterpoint. The beta-blocker significantly attenuated the terbutaline-induced effects in both cell lines, confirming that the observed changes were genuinely mediated through beta-adrenergic receptors rather than off-target actions of the agonist. Notably, the magnitude of inhibition was greater in the estrogen receptor positive cells, reinforcing the conclusion that this subtype is more exquisitely dependent on adrenergic input for the signaling responses measured. This detail carries potential clinical resonance, because it aligns with retrospective observations that beta-blocker therapy is associated with improved cancer-specific survival in breast cancer patients, and raises the possibility that patients with hormone receptor positive tumors might derive particular benefit.

The study builds on the same group’s earlier demonstration that estrogen receptor status governs how alpha-1 and alpha-2 adrenoceptors regulate cell survival and angiogenesis in breast cancer lines, and on work showing that estrogen modulates beta-2 adrenoceptor responses in immune cells through distinct intracellular pathways. Together, these findings sketch a picture in which the tumor’s hormonal identity rewires how it interprets nervous system signals. Mechanistically, the authors propose that estrogen receptor crosstalk selectively channels beta-2 adrenoceptor signaling into ERK-dependent versus CREB-dependent branches, producing the divergent proliferative and angiogenic outcomes, while parallel estrogen receptor independent routes account for the shared changes in nitric oxide, miR-21, VEGF-A, and CREB.

The implications cut in several directions. For researchers, the work is a caution against treating breast cancer as a single entity in stress-biology experiments: pooling estrogen receptor positive and negative models could average away effects that are real and opposite in each subtype. For clinicians, it adds mechanistic weight to the idea that beta-adrenergic signaling is a modifiable driver of tumor behavior, and suggests that estrogen receptor status might one day serve as a biomarker for selecting patients most likely to benefit from beta-blocker repurposing. For patients, it offers a tangible molecular account of how chronic stress physiology could influence tumor growth, at least for hormone-sensitive disease.

Important caveats remain. The findings come from cell lines in culture, where the tumor microenvironment, immune cells, vasculature, and the full neuroendocrine milieu of a living patient are absent. Concentrations, exposure durations, and the two-dimensional context of in vitro growth all shape signaling outcomes, and clinical translation will require validation in animal models and ultimately patient cohorts. Yet the core message is hard to ignore: the beta-2 adrenoceptor is not a simple on switch for cancer, but a context-dependent dial whose setting is determined by the estrogen receptor. As the authors conclude, both estrogen receptor dependent crosstalk and estrogen receptor independent adrenergic mechanisms contribute to the divergent outcomes, a duality that future therapeutic strategies targeting stress signaling in breast cancer will need to navigate with care.

Subject of Research: Estrogen receptor status determines how beta-2 adrenergic signaling regulates proliferation, angiogenic factors, and microRNAs in breast cancer cell lines

Article Title: Selective regulation of β2AR-mediated effects on cellular signaling mechanisms is governed by the estrogen receptor status of the breast cancer cell lines

Article References: Selective regulation of β2AR-mediated effects on cellular signaling mechanisms is governed by the estrogen receptor status of the breast cancer cell lines. (n.d.). https://doi.org/10.1007/s12032-026-03408-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03408-1

Keywords: breast cancer, beta-2 adrenoceptor, estrogen receptor, terbutaline, propranolol, ERK, CREB, VEGF-C, nitric oxide, miR-191, miR-21, cell signaling